Review for 10.1186/s12876-020-01264-5 (2020)

Reviewer ’s report  
 
Title: Reduced risk of post ERCP pancreatitis in statin u sers. 
 
Version: 0 Date: 09 Feb 2020  
 
Reviewer: Antonio Facciorusso  
 
Reviewer's report:  
Interesting article that confirms that statins may be of benefit in decreasing the rate of PEP. 
Recent ar ticles suggested a similar role also for other endoscopic procedure, for example EUS -
FNA. Pleace cite the article:  
 
Facciorusso A, Buccino VR, Prete VD, Antonino M, Contaldo A, Muscatiello N. Statins 
decrease the risk of acute pancreatitis after endoscopic  ultrasound fine -needle aspiration of 
pancreatic cysts [published online ahead of print, 2019 Oct 25]. Hepatobiliary Pancreat Dis Int. 
2019;S1499 -3872(19)30209 -7. doi:10.1016/j.hbpd.2019.10.001  
 
Please define the cut -off for consider "high dose" versus "lo w dose" statin. Usually a cumulative 
defined daily dose (cDDD) is considered and the cut -off chosen for statins is usually 365.  
 
Would you be able to perform a sub -analysis according to the type of statins (lipophilic versus 
hydrophilic)?  
 
Explain in the M ethods some technical details of the procedure. For example, when prophylactic 
indometacin was used?  
 
 
Are the  methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manu script:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, f ees, funding, or salary from an 
organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation t hat may in any way gain or lose 
financially from the publication of this manuscript, eithe r now or in the future?  
 
3. Do you hold or are you currently applying for any patents  relating to the content of the 
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relatin g to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have  no competing interests' 
below. If your reply is yes to any, please give details below.  
 
I declare that i have no competing interests  
 
 
 
I agree to the open peer review policy of the journa l. I understan d that my na me will be included 
on my report to the authors and, if the manuscript is accepted f or publication, my named report 
including any attachments I upload will be posted on the website along with the authors' 
responses. I agree for my  report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal